Chemotherapy with XXXX in combination with continuous infusion @entity5713 for metastatic @entity0 .

@entity1 @entity632 @entity137 @entity0 @entity2664 @entity1370 @entity221 @entity5713
The efficacy of @entity2664 in combination with @entity5713 was assessed in 156 @entity1 with metastatic @entity0 who had been treated previously with one or multiple chemotherapeutic regimens. @entity2664 was given by random assignment, either as a 10 mg/m2 single intravenous dose or in five consecutive daily fractions of 2 mg  2. @entity5713 was given as a continuous intravenous infusion of 1.2 mg/m2 daily for 5 days. In 115 evaluable @entity1 previously treated with @entity632 , 21 objective responses (18%) and 11 minor responses (10%) were observed with similar distribution in the two treatment groups. Median time to progression was 27 weeks and 23 weeks, respectively. Eight (32%) of 25 @entity1 who had not received @entity632 achieved objective remissions and two (8%) had minor responses. @entity137 effects were similar for the two treatment schedules. Major @entity137 were myelosuppression and @entity221 . Other @entity137 were mild. @entity1370 , presumably caused by @entity2664 , occurred in four @entity1 . The combination of @entity2664 and @entity5713 appeared to offer no advantage over single-agent therapy, probably because of the dosage reduction required by the overlapping myelosuppressive @entity137 .
